María José Sayas-Lloris
A5023013862- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
Hospital Universitario Doctor Peset
2021-2025
This PETHEMA PCR-LMA study aimed to evaluate whether mutations detected by NGS (VAF cut-off of ≥5%) correlate with NPM1, FLT3-ITD, FLT3-TKD, IDH1, and IDH2 using conventional PCR (analytical sensitivity 3%) in a nationwide network seven reference laboratories. Between 2019 2021, 1685 adult AML patients at least one centralized sample (NGS or PCR) primary diagnosis relapse/refractory episode were included. During this period, 1288 paired NGS/PCR samples (1094 diagnosis, 103 relapse 88...
Acute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological entities distinct mutational landscapes that translate into differential risks relapse and prognosis. Optimal postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study, we compared outcomes IRcyto AML recipients autologous (autoSCT) (n = 312) or allogeneic stem cell transplantation (alloSCT) 279) first complete remission (CR1)....
Gemtuzumab ozogamicin (GO) is a conjugate of monoclonal antibody and calicheamicin, which has been reapproved for the treatment acute myeloid leukemia (AML). AML patients with CD33 rs12459419 CC genotype might benefit from addition GO to intensive in contrast CT/TT genotypes. Nevertheless, contradictory results have reported. We sought shed light on prediction response polymorphism who were treated consolidation (n = 70) or reinduction 20) phase. The frequency distribution complete cohort...